| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Incannex Healthcare Inc.$2.99
+0.03 (+1.19%)
D 33Pipeline Score Richly Valued Biotech · Clinical
Market Cap
42.12 M
EPS
-17.18
P/E Ratio
-
Value Trade
535.43 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
321.00 K
Total Assets
80.28 M
Total Liabilities
5.05 M
Equity
75.23 M
D/E Ratio
12,345
-8.57 %
Week
-6.88 %
1 Month
-59.3 %
3 Month
-64.44 %
6 Month
-99.82 %
5 Year
-99.82 %
All Time
Cash Data
Cash Position
74.45 M
Monthly Burn
1.35 M
Runway
52.8 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
89.11 K
52 Week Range
2.49 - 49.80
% held by Insiders
0.94 %
% held by Institutions
10.81 %
Enterprise Value
-32.22 M
Total Shares
11.97 M
Short %
8.49 %
Float Shares
11.83 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Incannex Healthcare Inc.
145Total events
7Upcoming
46Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Enrollment Complete
Subscribe to view catalyst details
Event history 2
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Trial InitiationIHL-42X Low DoseApprovedTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D33
Pipeline Score $5M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 45%
Micro Cap (rank 503 of 913)
Percentile RankIncannex Healthcare Inc. faces pipeline headwinds (33/100), with $18M risk-adjusted pipeline value, with 2 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IHL-42X Low Dose Small molecule | Obstructive Sleep Apnea | Phase 2 | NCT06146101 | 8% | $9M | COMPLETED | 685 | VERY_FAST | B (68) | Jul 27, 2025 | MODERATE_RISK | HIGH Jul 27, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | — | Phase 2 | 2026-03-12 | Positive Phase 2 data has been reported for their drug candidates Read More | Innovating New Pathways to Relief NASDAQ:IXHL INVESTOR PRESENTATION February 2026 2 Corporate Presentation Legal Disclaimers This presentation of Incannex Healthcare Inc . (" Incannex ") contains "forward - looking state Read More | |
— | — | Phase 2 | 2026-03-12 | Positive Phase 2 data has been reported for their drug candidates Read More | Innovating New Pathways to Relief NASDAQ:IXHL INVESTOR PRESENTATION February 2026 2 Corporate Presentation Legal Disclaimers This presentation of Incannex Healthcare Inc . (" Incannex ") contains "forward - looking state Read More | |
— | — | Phase 2 | 2026-03-12 | Positive Phase 2 data has been reported for their drug candidates Read More | Innovating New Pathways to Relief NASDAQ:IXHL INVESTOR PRESENTATION February 2026 2 Corporate Presentation Legal Disclaimers This presentation of Incannex Healthcare Inc . (" Incannex ") contains "forward - looking state Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IXHL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IXHL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IXHL▲ +6.5%on this news
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility In addition to the A$6.0 million refund received, the Company expects a further approximate
Incannex Healthcare announced the receipt of A$6.0 million from the Australian Government's R&D Tax Incentive Program, reinforcing its financial position. The company expects an additional A$5.1 million in tax proceeds, bringing the total anticipated funds to over A$11.1 million, which will enhance its financial flexibility and support ongoing clinical developments. The CEO highlighted the importance of this non-dilutive capital, allowing the firm to manage its resources without the need to issue new shares or incurring debt.
Read more →IXHL▲ +7.9%on this newsshared move
Incannex Announces Initiation of Research Coverage by Alliance Global Partners MELBOURNE, Australia and
Incannex Healthcare has announced that Alliance Global Partners (AGP) has initiated research coverage of the company. This report, led by AGP's Managing Director, evaluates Incannex's clinical pipeline, development strategies, and market opportunities. The company views this coverage as a crucial step in enhancing its visibility among investors. However, there are inherent risks, such as the possibility that this coverage may not improve investor awareness as expected.
Read more →IXHLIncannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites
Incannex Healthcare has officially commenced its DReAMzz clinical study for IHL-42X, targeting obstructive sleep apnea. This study is viewed as a significant operational milestone, marking the progression toward late-stage development and potential regulatory pathways for the drug. All 14 clinical trial sites have been identified and prepared, and the necessary manufacturing and logistical support has been established. IHL-42X has shown promising Phase II trial results, which will guide further optimization and development in addressing the unmet needs in sleep medicine.
Read more →IXHL▼ -13.9%on this newsshared move
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development Recognition highlights strong clinical progress and growing global validation of Incannex's inn
Incannex Healthcare has won the 'Best New Technology Solution for Drug Development' award at the 10th annual MedTech Breakthrough Awards for its lead drug candidate, IHL-42X. This oral therapy aims to treat obstructive sleep apnea by combining dronabinol and acetazolamide, reflecting significant clinical progress. The recognition reinforces the company's innovative approach in the biopharmaceutical sector and their ongoing efforts in advancing IHL-42X through late-stage development.
Read more →IXHL▲ +8.5%on this news
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness Company's oral synthetic psilocybin program advances within significant
Incannex Healthcare's PSX-001 program for treating Generalized Anxiety Disorder has received support from a recent White House Executive Order aimed at accelerating access to psychedelic treatments. The program, which has demonstrated significant improvements in clinical trials, stands to benefit from a more conducive regulatory framework. CEO Joel Latham emphasized the urgent need for new treatment options for patients suffering from anxiety disorders, making this initiative a pivotal moment for the company and its patients. With over $70 million in cash, Incannex is well-positioned to advance PSX-001 through further clinical development.
Read more →IXHLIncannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trad
Incannex Healthcare Inc. has reactivated its share repurchase program following a period of inactivity, indicating the company's confidence in its market valuation and future potential. The company holds approximately $75 million in cash and has no debt, positioning it favorably as it advances its clinical pipeline, including treatments for obstructive sleep apnea and generalized anxiety disorder. The board believes that current market perceptions do not accurately reflect its financial strength and progress in clinical programs.
Read more →IXHL▲ +15.8%on this newsshared move
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X
Incannex Healthcare announced a partnership with the AASM Foundation to support research in combating sleep apnea. The collaboration includes a grant for junior investigators and highlights Incannex's commitment to advancing its lead candidate, IHL-42X, an oral treatment for obstructive sleep apnea, which has demonstrated positive results in Phase 2 trials. Additionally, the company has received FDA Fast Track designation, facilitating a quicker path to market for its innovative therapies. This partnership aims to foster further research in sleep medicine and aid those affected by this chronic condition.
Read more →IXHL▼ -6.6%on this news
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optim
Incannex Healthcare Inc. has reported a strong financial position with $75 million in cash and no debt, strengthening its ability to develop its clinical pipeline. The company plans to utilize financing proceeds to fund the DReAMzz Phase 2 study for its drug candidate IHL-42X, aimed at treating obstructive sleep apnea. With institutional investors backing their financing efforts, Incannex is set to advance both IHL-42X and PSX-001 for generalized anxiety disorder, while positioning itself for further capital-efficient growth and potential optimizations in future phases of development.
Read more →IXHLIncannex Regains Compliance with Nasdaq Minimum Bid Price Requirement Melbourne and New York
Incannex Healthcare Inc. (Nasdaq: IXHL) has announced that it has regained compliance with the Nasdaq minimum bid price requirement after its stock maintained a closing price of at least $1.00 per share for eleven consecutive business days. This confirmation ensures the company's continued listing on the Nasdaq Capital Market. With about $75 million in cash and no debt, Incannex is well-positioned to advance its clinical programs, including IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder, both of which have shown positive clinical results.
Read more →IXHL▼ -48.4%on this newsshared move
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEW YORK and MELBOURNE, Australia
Incannex Healthcare Inc. has announced a registered direct offering to raise $10 million by selling 2,000,000 shares of common stock. The offering, expected to close on March 13, 2026, involves warrants that could increase total potential funding to $23 million if exercised. The funds are primarily intended to support the DReAMzz Phase 2 study for the candidate IHL-42X, while the company also has prior cash reserves for Phase 3 development planned for late 2027. The issuance is seen as a positive move for the company's financial stability and operational progress.
Read more →IXHL▼ -48.4%on this newsshared move
Innovating New Pathways to Relief NASDAQ:IXHL INVESTOR PRESENTATION February 2026 2 Corporate Presentation Legal Disclaimers This presentation of Incannex Healthcare Inc . (" Incannex ") contains "forward - looking state
Incannex Healthcare Inc. delivered an investor presentation highlighting its innovative pipeline focused on chronic conditions like Obstructive Sleep Apnea and Generalized Anxiety Disorder. The presentation included forward-looking statements about their ability to achieve objectives, regulatory interactions, and market potential. Positive Phase 2 data has been reported for their drug candidates, and the company is described as well-funded with significant cash reserves to advance its clinical programs. However, the report also outlines various risks that could impact their future success.
Read more →IXHL▼ -15.4%on this news
Incannex Announces Reverse Stock Split Incannex's common stock is expected to begin trading on a post-split adjusted basis on
Incannex Healthcare Inc. has announced a 1-for-30 reverse stock split of its common stock, set to take effect on February 26, 2026. The move intends to increase the share price to comply with Nasdaq's listing requirements, following approval from stockholders in May 2025. The reverse split will reduce the outstanding shares significantly, from approximately 358 million to about 11.9 million. Stakeholders will see automatic adjustments in their holdings, with no fractional shares issued, as Incannex aims to navigate compliance challenges and continue its clinical development programs.
Read more →IXHLIncannex Healthcare Announces Additional Appointments to Clinical Advisory Board Expands clinical expertise to support disciplined advancement of the PSX-001 program MELBOURNE, Australia and
Incannex Healthcare Inc. has expanded its Clinical Advisory Board by appointing three new members with significant expertise in psychiatry and clinical development. This strategic move aims to enhance the guidance on the clinical and regulatory path for its PSX-001 program, which is being developed as a treatment for generalized anxiety disorder. The newly appointed members bring extensive experience and leadership in their respective fields, which will support informed decision-making as the company progresses its developmental efforts.
Read more →IXHLIncannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of development MELBOURNE, Australia and
Incannex Healthcare has announced the formation of a Clinical Advisory Board (CAB) to support the PSX-001 development program targeting generalized anxiety disorder. The CAB is composed of leading experts in psychiatry and neurobiology and will provide clinical and regulatory guidance as the program advances. Key roles include advising on clinical trial design and regulatory engagement, which aims to manage risks and strengthen execution through informed decisions.
Read more →IXHLIncannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards MELBOURNE, Australia and NEW YORK - January 15 th , 2026 - (GLOBE NEWSWIRE)
Incannex Healthcare has been awarded the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its product candidate IHL-42X, which aims to treat obstructive sleep apnea. This award highlights the company's dedication to addressing unmet medical needs in the respiratory field through innovative combination therapies. The development of IHL-42X is supported by a robust Phase 2 clinical program focusing on evidence-based outcomes and patient-reported measures. The recognition serves to emphasize Incannex's broader mission in developing novel therapeutic solutions targeting chronic conditions.
Read more →IXHLIncannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 Company enters 2026 with over $70 million in cash, two positive Phase 2 programs, FDA Fast Track Designation and runwa
Incannex Healthcare has reported significant progress in 2025, noting two positive Phase 2 clinical readouts for its programs targeting obstructive sleep apnea and generalized anxiety disorder. The company has secured FDA Fast Track designation for its leading candidate, IHL-42X, and is well-funded entering 2026 with over $70 million in cash. This financial backing positions Incannex for continued execution and transition into later-stage development of its drug candidates. The firm also established a Clinical Advisory Board to enhance its strategic direction in advancing treatment solutions.
Read more →IXHL▲ +12.7%on this news
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) MELBOURNE, Australia and
Incannex Healthcare Inc. has received Fast Track designation from the FDA for its oral fixed-dose combination product, IHL-42X, aimed at treating obstructive sleep apnea (OSA). The designation follows favorable outcomes from three clinical trials, including significant reductions in the Apnea-Hypopnea Index. This regulatory milestone is seen as a pivotal step in facilitating expedited development of a new treatment option for OSA patients. Incannex is committed to working closely with the FDA towards late-stage development and commercialization.
Read more →IXHL▲ +17.8%on this news
Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus Company outlines continued progress across clinical, regulatory, and capital initiatives positioning f
Incannex Healthcare Inc. has provided a shareholder update emphasizing its clinical advancements and strategic focus for the end of 2025. Key highlights include promising results from the Phase 2 clinical trials for IHL-42X, which showed up to an 83% reduction in AHI for obstructive sleep apnea, and PSX-001 for anxiety disorders. The company has also secured a Nasdaq extension, which is expected to enhance its financial positioning. Incannex is actively exploring partnerships and maintaining a disciplined approach to capital management as it progresses towards late-stage development.
Read more →IXHLIncannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement MELBOURNE, Australia and NEW YORK, USA - October 22 - Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmac
Incannex Healthcare Inc. has been granted a 180-day extension by the Nasdaq to meet its minimum bid price requirement. The company now has until April 20, 2026, to ensure its shares maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days. They have successfully launched two Phase 2 clinical data packages and are well-positioned to execute their strategy, maintaining compliance with other Nasdaq criteria. This extension provides Incannex with the opportunity to address the deficiency while preserving flexibility in their operational objectives.
Read more →IXHLIncannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder Psi-GAD delivers statistically significant and clinically meaningful improvements across validated measu
Incannex Healthcare reported positive results from its Phase 2 clinical trial of PSX-001 for Generalised Anxiety Disorder. The study involved 73 adults and showed statistically significant improvements in anxiety and quality of life measures, with the treatment effects observed to be durable over an 11-week follow-up. Safety evaluations indicated that the therapy was well tolerated with no serious adverse events, reinforcing PSX-001's potential as a leading psilocybin-assisted treatment for GAD. Following this success, the company aims to progress towards late-stage development, which could enhance treatment accessibility for patients.
Read more →IXHL▲ +28.5%on this news· ran to +62% by day 1shared move
Incannex Healthcare Authorizes $20 Million Share Repurchase Program Melbourne, Australia and New York, USA - August 22 - Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmace
Incannex Healthcare has authorized a $20 million share repurchase program aimed at buying back its common stock. The Board of Directors believes this move demonstrates confidence in the company's clinical pipeline and long-term prospects. The repurchase program will be executed based on market conditions and available resources. CEO Joel Latham emphasized that this strategy is part of their commitment to enhance shareholder value while advancing their late-stage clinical pipeline.
Read more →IXHLIncannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea Exit interviews and clinical results reinforce strong potential for meaningful improvement
Incannex Healthcare Inc. announced positive findings from the RePOSA Phase 2 trial for its drug IHL-42X, aimed at treating obstructive sleep apnoea (OSA). Patient-reported outcomes highlighted significant improvements in sleep quality and daily experiences, supporting the clinical data. Joel Latham, CEO, noted reductions in Apnoea-Hypopnoea Index of up to 83%, indicating strong therapeutic potential. However, concerns about stock volatility and market valuation contrast with the encouraging trial results.
Read more →IXHL▼ -33.5%on this news· ran to -56% by day 1
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term Melbourne, Australia
Incannex Healthcare Inc. has confirmed its strong cash position, currently holding about $50 million, and clarified that it has no immediate plans to fully utilize its At-The-Market (ATM) offering. The decision allows for strategic flexibility regarding capital access, especially as the company progresses its innovative drug candidates. Furthermore, recent Phase 2 clinical trial results for IHL-42X have shown significant promise, leading the company to prepare for Phase 3 development. However, Incannex acknowledges potential risks associated with market dynamics and the need for future capital raising.
Read more →IXHL▼ -17.8%on this news· ran to -58% by day 3shared move
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X
Incannex Healthcare has announced positive topline results from its Phase 2 RePOSA trial for IHL-42X, a novel treatment for obstructive sleep apnoea (OSA). The trial indicated statistically significant improvements across key clinical endpoints, including a reduction in the Apnea-Hypopnoea Index of up to 83%. Notably, IHL-42X demonstrated an excellent safety profile, with no serious adverse events recorded. With over 900 million people affected by OSA globally and no approved treatments currently available, these results could position IHL-42X as a leading therapeutic option in this space.
Read more →IXHL▼ -35.6%on this news· ran to -46% by day 3shared move
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo NEW YORK and
Incannex Healthcare has appointed Dr. Charlene E. Gamaldo to its Clinical Advisory Board to support the development of its IHL-42X for obstructive sleep apnea (OSA). Dr. Gamaldo's extensive experience in sleep medicine is expected to add significant value to the program. The company anticipates a Phase 2 data readout for IHL-42X next week, which could impact its progression through clinical trials. IHL-42X is a combination therapy that targets physiological pathways associated with OSA, aiming to benefit a broader patient population beyond those who are just obese.
Read more →IXHL▲ +10%on this news
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch NEW YORK and
Incannex Healthcare has announced the appointment of Dr. Douglas B. Kirsch to its Clinical Advisory Board to support its IHL-42X Obstructive Sleep Apnea program. Dr. Kirsch, a recognized expert in sleep medicine, will provide pivotal experience as the company progresses towards late-stage development of IHL-42X, which is designed to treat obstructive sleep apnea through a unique combination of dronabinol and acetazolamide. The company anticipates topline Phase 2 data from its U.S. RePOSA study by July 2025, with plans for Phase 3 initiation later in the year.
Read more →IXHLIncannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X Top-line results expected July 2025 as development of first-in-class OSA drug advances NEW YORK and
Incannex Healthcare Inc. has reached a significant milestone by achieving database lock for the RePOSA Phase 2 trial of IHL-42X, its lead candidate for treating obstructive sleep apnoea. This successfully confirms the completion of clinical data collection, paving the way for final statistical analysis. The company anticipates top-line results will be available by July 2025, reinforcing the potential impact of its first-in-class therapy targeting a widespread condition with limited treatment options. This advancement reflects the growing confidence in the clinical program's progress and its commitment to addressing a critical health issue.
Read more →IXHL▲ +5.5%on this newsshared move
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy Expanded platform improves access, scales operations, and advances Incannex's position in next-generat
Incannex Healthcare has established a 50:50 joint venture with Mind Medicine Australia to enhance access to psychedelic-assisted therapies in Melbourne. This initiative is expected to improve clinical operations and expand service capacity for individuals suffering from complex mental health issues. The partnership aims to create a Centre of Excellence that will train clinicians and provide best-in-class care. Patient intake is anticipated to begin soon due to strong early demand for these innovative treatment options.
Read more →IXHL▲ +14.6%on this newsshared move
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milesto
Incannex Healthcare has successfully canceled all outstanding Series A Warrants, leading to a streamlined capital structure and removal of potential dilution. This strategic execution via their At-The-Market facility has raised the necessary funds and aligns with upcoming key Phase 2 clinical milestones. The company is focusing on its lead candidate, IHL-42X, designed to treat obstructive sleep apnea, which affects millions globally. Anticipated topline results from ongoing trials are expected in July 2025, highlighting the company's commitment to addressing significant health needs.
Read more →IXHLIncannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program NEW YORK and
Incannex Healthcare Inc. has expanded its IHL-42X Clinical Advisory Board by appointing four leading experts in the field of obstructive sleep apnea (OSA). This advisory board will support the advancement of the IHL-42X treatment, which is designed to address the underlying pathophysiology of OSA. The company is preparing to announce Phase 2 topline data in July 2025 and will initiate a Phase 3 study later in the year. IHL-42X has shown promising results in previous trials and aims to serve a population that is significantly underdiagnosed and undertreated for OSA.
Read more →IXHLIncannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance Streamlined U.S.-only study design builds on Phase 2 momentum for IHL-42X in obstructive sleep apnea NEW YORK and
Incannex Healthcare Inc. has received FDA clearance to advance its IHL-42X RePOSA trial into Phase 3, targeting obstructive sleep apnea. This pivotal trial will utilize a streamlined U.S.-only study design, leveraging successful strategies from Phase 2 to enhance efficiency. The expected inclusion of approximately 30 sites provides a solid foundation for rapid recruitment and trial execution. There is anticipation of significant outcomes as the study aims to establish IHL-42X as a leading oral therapy for a condition affecting a billion individuals worldwide.
Read more →IXHL▼ -14.8%on this news· ran to -26% by day 3shared move
Incannex Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of Key Phase 2 Results Melbourne, Australia and New York, USA
Incannex Healthcare Inc. has signed an agreement to cancel 172 million Series A Warrants, eliminating the possibility of 347.2 million shares entering the market. This strategic move is designed to strengthen the company's capital structure ahead of upcoming Phase 2 results for its IHL-42X drug, aimed at treating obstructive sleep apnea. The decision reflects Incannex's commitment to managing dilution risk while bolstering shareholder value amidst critical developments in its clinical programs.
Read more →IXHL▲ +20.1%on this news
Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data NEW
Incannex Healthcare Inc. has announced the successful cancellation of 50.4% of its Series A Warrants, reducing the potential for future share dilution. The company also raised $12.5 million through its at-the-market facility to strengthen its financial position ahead of the IHL-42X Phase 2 clinical trial, which targets obstructive sleep apnea. This strategic decision emphasizes Incannex's proactive approach to capital management and alignment with shareholder interests, aiming for long-term value creation.
Read more →IXHL▼ -23.1%on this newsshared move
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42
Incannex Healthcare Inc. has announced the successful completion of patient dosing in the Phase 2 portion of its clinical study for IHL-42X, an oral treatment for obstructive sleep apnea (OSA). The company reports promising pharmacokinetic and safety data, indicating potential as a first-in-class therapy. With the results set to be analyzed soon, Incannex is preparing for a critical interaction with the FDA, scheduled for the third quarter of 2025. The company also highlights growing interest from clinical sites and trial participants, suggesting a strong foundation for the ongoing development of IHL-42X.
Read more →IXHLIncannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants NEW YORK and
Incannex Healthcare Inc. announced that it has entered into agreements to potentially reduce up to 50.4% of the Series A Warrants held by shareholders. This move is expected to lessen stockholder dilution and involves utilizing funds from its ATM sales agreement for payment. The company is also advancing its clinical candidate, IHL-42X, in a Phase 2/3 clinical trial targeting obstructive sleep apnea, with promising early results reported. A special meeting for stockholder approval is scheduled for May 27, 2025.
Read more →IXHL▼ -61.6%on this newsshared move
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates NEW YORK and
Incannex Healthcare Inc. reported its fiscal Q3 2025 financial results, highlighting significant progress in its IHL-42X program aimed at treating obstructive sleep apnea. The company's successful completion of Phase 2 enrollment and positive clinical data have positioned it well for upcoming milestones. However, ongoing operational costs and an accumulated deficit raise concerns about financial sustainability. The firm remains committed to advancing its innovative combination therapies for chronic conditions.
Read more →IXHLIncannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) Topline Phase 2 clinical data expected in the first half 2025 NEW YORK
Incannex Healthcare announced the completion of patient enrollment for Phase 2 of the RePOSA Phase 2/3 trial for IHL-42X, a novel oral treatment for obstructive sleep apnea (OSA). The trial aims to evaluate the drug's safety and efficacy, with topline results expected in the first half of 2025. IHL-42X targets physiological mechanisms of airway obstruction, representing a unique therapeutic approach in a field lacking approved pharmaceutical treatments for OSA. The trial has exceeded typical enrollment timelines, reflecting the pressing need for effective solutions in managing this condition.
Read more →IXHL▼ -19.4%on this news· ran to -31% by day 3
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinica
Incannex Healthcare Inc. has announced the pricing of a $12.5 million private placement aimed at funding the advancement of its IHL-42X oral medication for obstructive sleep apnea. The offering involves the sale of 11,574,090 shares at $1.08 each, along with Series A warrants. Proceeds will support the completion of the Phase 2 study in the U.S. and the expansion into a Phase 3 study. The transaction is expected to close around March 10, 2025, pending customary conditions.
Read more →IXHLIncannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Applica
Incannex Healthcare Inc. reported positive financial results and significant updates regarding its clinical trials for its oral drug IHL-42X aimed at treating obstructive sleep apnea (OSA). The company announced successful pharmacokinetics data supporting the drug's efficacy and safety while detailing strong recruitment for the global Phase 2/3 RePOSA clinical trial. Additionally, Incannex's advisory board, featuring experts from ResMed, aims to strengthen the trial's guidance. Upcoming results from the U.S. Phase 2 trial are anticipated in the first half of 2025.
Read more →IXHL▲ +10.9%on this news
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board Dr. Wimms brings extensive industry and clinical development experience in sleep medicine inn
Incannex Healthcare has announced the appointment of Dr. Alison Wimms, Ph.D., to its newly formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board. Dr. Wimms, with over 20 years of experience in sleep medicine, will guide the late-stage clinical development of IHL-42X, an oral combination treatment currently in Phase 2/3 studies. The advisory board's establishment reflects Incannex's commitment to innovation in OSA treatment, with a global clinical trial underway aimed at enhancing patient treatment outcomes.
Read more →IXHL▼ -12%on this news
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea Demonstrated bioavailability of IHL-42X, Incan
Incannex Healthcare has announced positive topline results from a pharmacokinetics study of IHL-42X, an oral combination medicine for treating obstructive sleep apnea. The study confirmed the bioavailability of the drug, supporting a potential FDA 505(b)(2) application. The findings are consistent with expectations and show a good safety profile, with no serious adverse events reported. The study's results will assist in advancing IHL-42X through upcoming clinical trials.
Read more →IXHLIncannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex
Incannex Healthcare Inc. reported its fiscal full year 2024 financial results, highlighting a strategic financing agreement with Arena Investors that provides access to up to $59 million in gross proceeds. The company has made significant progress in clinical trials, including positive data from PSX-001 for anxiety and advancing its Phase 2/3 trial for IHL-42X aimed at obstructive sleep apnea. However, the report also reflects a decline in total current assets compared to the previous year, presenting potential financial concerns moving forward.
Read more →IXHLIncannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors Incannex to Receive Funding of Up to $10 Million in Convertible Notes and $50 Million Equity Line of Credit NEW YORK and MELBOU
Incannex Healthcare has announced a strategic financing deal worth up to $60 million with Arena Investors. The agreement includes $10 million in secured convertible notes and a $50 million equity line of credit. The funds are intended to support ongoing clinical trials for the company's drug candidates, including treatments for obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. Incannex plans to allocate the funding based on strategic needs to ensure the further development of its therapeutic programs.
Read more →IXHL▲ +723.7%on this news· ran to +800% by day 3
DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Incannex Healthcare Inc., a Delaware corporation (the "Company") is a summary only. This summary is subject to the General Corporation Law of
The article provides a comprehensive overview of the capital stock structure of Incannex Healthcare Inc. It outlines the types of shares authorized for issuance, including common and preferred stock, and details the rights associated with these shares. There are provisions highlighting voting rights, dividend distribution, and conditions for liquidation. Additionally, it discusses potential limitations on stockholder actions and the board of directors' authority regarding share issuance.
Read more →IXHLMarket Announcement 17 November 2023 Incannex Healthcare Limited (ASX: IHL) - Suspension from Quotation Description The securities of Incannex Healthcare Limited ( IHL') will be suspended from quotation at the close of t
Incannex Healthcare Limited (ASX: IHL) will have its securities suspended from quotation at the close of trading on November 17, 2023. This suspension follows the Federal Court of Australia's approval of a scheme of arrangement for Incannex Healthcare Inc. to acquire all issued securities in IHL. The trading halt is a significant event for shareholders and reflects ongoing restructuring efforts within the company.
Read more →IXHL▲ +5.9%on this newsshared move
Date: 17 November 2023 Public Announcement (Nasdaq: IXHL) (ASX: IHL) Computershare will be appointed US Transfer Agent and Registrar to facilitate Transfer Capabilities for Nasdaq-listed shares Melbourne, Australia, 17 N
Incannex Healthcare Limited (Nasdaq: IXHL) has announced the appointment of Computershare as its US Transfer Agent and Registrar. This change aims to facilitate the transition of shares from ASX to Nasdaq for security holders as part of an approved scheme of arrangement. Key features of Computershare's platform will include technical support and a dedicated hotline to assist shareholders throughout the process. The transition is expected to begin with shares listing on Nasdaq by November 28, 2023.
Read more →IXHLAppendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
Incannex Healthcare Limited (IHL) reported changes in directors' interests, with Peter Widdows acquiring 230,954 ordinary shares and Troy Valentine acquiring 11,091,950 ordinary shares. Neither director disposed of any securities, suggesting a bullish outlook. The changes are in line with ASX listing rules, reflecting transparency in director transactions. The details of the shares and options held by the directors are also provided in compliance with regulatory obligations.
Read more →IXHLDate: 26 October 2023 Public Announcement (ASX: IHL) (Nasdaq: IXHL) Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement Melbourne, Australia
Incannex Healthcare provided its quarterly report detailing significant advancements in its clinical trials, including FDA approval for its IHL-42X Phase 2/3 trial targeting obstructive sleep apnoea. The initial proof of concept showed promising results, indicating potential marketability of IHL-42X if continued success is observed. Additionally, the company is preparing to launch its Clarion Clinics for psychedelic-assisted therapies, with positive interim feedback on regulatory approvals. Strong patient interest has been noted, enhancing hopes for successful treatment outcomes.
Read more →IXHLIncannex Healthcare Limited ABN 93 096 635 246 Appendix 4E For the year ended 30 June 2023 Information for ASX under listing rule 4.3A Reporting Period: 30 June 2023 Comparative Period: 30 June 2022 2.0 Results for annou
Incannex Healthcare Limited published its annual report for the year ending June 30, 2023, revealing a substantial loss of approximately $19.98 million, compared to $14.9 million the previous year. Despite financial losses, the company highlighted major advancements in its clinical trial programs, including successful results from the IHL-42X trial for obstructive sleep apnoea and progress in its cannabinoid therapy IHL-675A. Furthermore, the company has received FDA approval to open its Investigational New Drug file, paving the way for a pivotal Phase 2/3 trial. The report also notes the expected completion of a Phase 2 clinical trial for psilocybin-assisted therapy for generalized anxiety disorder in early 2024.
Read more →IXHLRules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Incannex Healthcare Limited ABN/ARBN Financial year ended: 93 093 635 246 30 JUNE 2023 Our
Incannex Healthcare Limited has released its Corporate Governance Statement, which confirms adherence to the Corporate Governance Council Principles and Recommendations. It reports compliance status as of August 30, 2023, and includes details relevant to the board's structure and management oversight. However, the entity also indicates that not all recommendations have been fully implemented, highlighting potential areas for improvement.
Read more →IXHLDate: 28 July 2023 Public Announcement (ASX: IHL) (Nasdaq: IXHL) Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement Melbourne, Australia
Incannex Healthcare Limited reported positive developments in its June 2023 quarterly activities report. The company received ethics approval to commence a clinical trial for its drug IHL-42X aimed at treating Obstructive Sleep Apnea (OSA) and successfully submitted an Investigational New Drug application to the FDA. Incannex also plans to open a psychedelic-assisted psychotherapy clinic in Melbourne, anticipating significant market potential. Additionally, preliminary results from the Phase 1 clinical trial of IHL-675A indicate favorable safety and efficacy compared to existing treatments.
Read more →IXHLIncannex Healthcare Limited ABN 93 093 635 246 Level 39, Rialto South Tower 525 Collins Street Melbourne VIC 3000 Changes to Company Capital Incannex Healthcare Limited ("the Company") wishes to advise two changes to its
Incannex Healthcare Limited has announced changes to its company capital involving the release of IHL ordinary shares. The announcement details that 3,784,204 shares have been released to executives and 533,333 shares to employees as part of their remuneration packages. This release follows the completion of vesting periods for the executives, fostering confidence in the company's governance and alignment with performance incentives.
Read more →IXHLP s y c h en n e x P t y L td C o m p a n y U p d a t e Market Update May 2023 Psychennex Pty Ltd A Division of Incannex Healthcare Ltd (IHL - ASX) (IXHL - NASDAQ) Disclaimer Not an offer of Securities : This document ha
Psychennex Pty Ltd, a division of Incannex Healthcare Ltd, has provided an update highlighting its position in the Australian psychedelics sector. The company focuses on psychedelic-assisted psychotherapy to address mental health issues that traditional treatments have not effectively managed. It holds significant intellectual property and is involved in various clinical trials centered on enhancing treatment options for debilitating mental health conditions. The document emphasizes the company's innovative approach and active role in expanding the psychedelic treatment landscape, although it includes disclaimers regarding the speculative nature of investments.
Read more →IXHLIHL - 675A P h a s e 1 c li n i c a l t r i a l t o a s s e s s s a f e t y an d p h a r m a c o k i n e t i c s a s a p o t e n t i al a n t i - i n f i a m m a t o r y d r u g c and i d a t e A S X T i c k e r : I H L
Incannex Healthcare Limited reports positive results from its Phase 1 clinical trial of IHL-675A, a cannabinoid combination drug aimed at anti-inflammatory treatment. The trial involved 36 patients and confirmed that IHL-675A was well tolerated with no serious adverse events. Additionally, the drug showed strong efficacy signals in reducing inflammatory disease severity compared to its individual components. These findings suggest potential for further clinical assessment of IHL-675A.
Read more →IXHL▼ -8.3%on this news
Date: 27 April 2023 Public Announcement (ASX: IHL) (NASDAQ: IXHL) Incannex Healthcare March 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement Melbourne, Australia
Incannex Healthcare has released its quarterly activities report detailing several developments in its clinical programs. The company is focused on cannabinoid products and psychedelic therapies, planning to commercialize psychedelic-assisted psychotherapy clinics in Australia with an addressable market projected to surpass $2 billion within three years. Promising interim results from a clinical trial suggest a high likelihood of significant benefits from psilocybin treatment for anxiety disorders. Incannex is set to open its first model clinic in Melbourne by Q3 2023 as part of its expansion strategy.
Read more →IXHLINCANNEX HEALTHCARE LIMITED ABN 93 096 635 246 (and controlled entities) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMEBR 2022 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A.3 Appendix 4D Half Year Report for the
Incannex Healthcare Limited reported a substantial increase in net losses for the half-year ended December 31, 2022, totaling A$8,529,015 compared to A$5,244,874 for the same period in the previous year. Despite this financial struggle, the company made strategic advancements in their drug development programs and successfully raised A$13 million in new capital. The report highlights ongoing research into cannabinoid and psychedelic-assisted therapies, including significant clinical trials. No dividends have been paid during this period.
Read more →IXHLMarket Announcement 1 December 2022 Incannex Healthcare Limited (ASX: IHL) - Trading Halt Description The securities of Incannex Healthcare Limited ( IHL') will be placed in trading halt at the request of IHL, pending it
Healthcare Limited (ASX: IHL) - Trading Halt securities of Incannex Healthcare Limited ( IHL') will be placed in trading halt at the request of IHL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier
Read more →IXHL▼ -7.7%on this news
Incannex Healthcare Limited ACN 096 635 246 ADDENDUM TO NOTICE OF ANNUAL GENERAL MEETING For the annual general meeting of the Company to be held at the offices of Thomson Geer at Level 27 Exchange Tower, 2 The Esplanade
Incannex Healthcare Limited ACN 096 635 246 ADDENDUM TO NOTICE OF ANNUAL GENERAL MEETING For the annual general meeting of the Company to be held at the offices of Thomson Geer at Level 27 Exchange Tower, 2 The Esplanade, Perth on Tuesday, 29 November 2022 at 2:00 pm (Perth time)
Read more →IXHLIncannex Healthcare Limited ACN 096 635 246 NOTICE OF ANNUAL GENERAL MEETING For the annual general meeting of the Company to be held at the offices of Thomson Geer at Level 27 Exchange Tower, 2 The Esplanade, Perth on T
OF ANNUAL GENERAL MEETING the annual general meeting of the Company to be held at the offices of Thomson Geer at Level 27 Exchange Tower, 2 The Esplanade, Perth on Tuesday, 29 November 2022 at 2:00 pm (Perth time). Board considers that the health, safety and welfare of the Com
Read more →IXHLAnnual report Incannex Healthcare Limited ASX: IHL | NASDAQ: IXHL Limitless P o t e n t i a l O u r M i s s i o n i s t o c r ea t e fi r s t - i n - c la s s p h a r m a c e u t i c a l d r u g s an d t h e r a p i e s
2022 Annual report Incannex Healthcare Limited ASX: IHL | NASDAQ: IXHL Limitless P o t e n t i a l O u r M i s s i o n i s t o c r ea t e fi r s t - i n - c la s s p h a r m a c e u t i c a l d r u g s an d t h e r a p i e s f o r p a t i e n t s w i t h u n m e t m ed i c a l n
Read more →IXHLIncannex Healthcare Limited ABN 93 096 635 246 Appendix 4E Preliminary Final Report For the year ended 30 June 2022 Information for ASX under listing rule 4.3A Reporting Period: 30 June 2022 Comparative Period: 30 June 2
Incannex Healthcare Limited Preliminary Final Report For the year ended 30 June 2022 Information for ASX under listing rule Reporting Period: 30 June 2022 Comparative Period: 30 June 2021 The financial statements contained in the Appendix 4E are based on the accounts which
Read more →IXHLCompany Overview | ASX Ticker: IHL NASDAQ Ticker: IXHL Disclaimer Disclosure and Disclaimer This presentation has been prepared by Incannex Healthcare Limited ("Incannex" or the "Company) for informational purposes only
Company Overview | ASX Ticker: IHL NASDAQ Ticker: IXHL Disclaimer Disclosure and Disclaimer This presentation has been prepared by Incannex Healthcare Limited ("Incannex" or the "Company) for informational purposes only and not for any other purpose . Such offering of securities
Read more →IXHL▲ +11.2%on this news· ran to +49% by day 3
Notice of extraordinary general meeting and explanatory statement Incannex Healthcare Limited ACN 096 63 246 Date: 09 June 2022 Time: 9.00 am (Sydney time) Location: This meeting will be conducted as a virtual meeting, a
of extraordinary general meeting and explanatory statement Date: 09 June 2022 Time: 9.00 am (Sydney time) Location: This meeting will be conducted as a virtual meeting, accessible online Meeting will be held virtually. Shareholders will be able to participate in the Meeting by
Read more →IXHLINCANNEX HEALTHCARE LIMITED ABN 93 096 635 246 (and controlled entities) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER 2021 PROVIDED TO THE ASX UNDER LISTING RULE 4.2A.3 Appendix 4D Half Year Report for the
INCANNEX HEALTHCARE LIMITED (and controlled entities) HALF-YEAR INFORMATION FOR THE SIX MONTHS ENDED 31 DECEMBER PROVIDED TO THE ASX UNDER LISTING RULE 4.2A.3 Half Year Report for the six months to 31 December 2021 INCANNEX HEALTHCARE LIMITED Report for the half year ended
Read more →Competitive Position
How IXHL ranks across every disease it competes inCompetitive Position is a premium feature
See how IXHL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial